

WHO Expert Committee on Drug Dependence

Forty-first report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 1 8

WHO Expert Committee on Drug Dependence

Forty-first report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Expert Committee on Drug Dependence: forty-first report

(WHO Technical Report Series, No. 1018)

ISBN 978-92-4-121027-0

ISSN 0512-3054

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Drug Dependence: forty-first report. Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1018). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout L'IV Com Sàrl

Printed in France



Contents

WHO Expert Committee on Drug Dependence	IV
Abbreviations	VI
Introduction	1
Open session	1
Closed session	3
Declarations of interest	4
1. Update on priorities from international agencies	5
1.1 United Nations Office on Drugs and Crime (UNODC)	5
1.2 International Narcotics Control Board (INCB)	6
1.3 WHO	7
2. Review of substances	10
3. Fentanyl analogues	11
3.1 Para-fluoro-butylfentanyl	11
3.2 Para-methoxy-butylfentanyl	12
3.3 Ortho-fluorofentanyl	14
3.4 Methoxyacetylfentanyl	15
3.5 Cyclopropylfentanyl	17
4. Synthetic cannabinoids	19
4.1 ADB-FUBINACA	19
4.2 FUB-AMB	20
4.3 ADB-CHMINACA	22
4.4 CUMYL-4CN-BINACA	24
5. Cathinone	26
5.1 N-ethylnorpentylone	26
6. Medicines	28
6.1 Pregabalin	28
6.2 Tramadol	30
7. Cannabis and cannabis-related substances	34
7.1 Cannabis and cannabis resin	37
7.2 delta-9-tetrahydrocannabinol (Δ^9 -THC; dronabinol)	41
7.3 Tetrahydrocannabinol (isomers of THC)	47
7.4 Extracts and tinctures of cannabis	50
7.5 Cannabidiol preparations	53
Acknowledgements	56
References	57

WHO Expert Committee on Drug Dependence

Geneva, Switzerland, 12–16 November 2018

Members

Professor Patrick M. Beardsley, Professor of Pharmacology and Toxicology, Institute for Drug and Alcohol Studies, and Centre for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, United States of America

Professor Bruna Brands, Professor of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Canada

Dr Ifeoma Toyin Ekwere, Senior Lecturer, Department of Anaesthesiology, University of Benin, Nigeria

Professor Simon Elliott, Consultant Forensic Toxicologist, Elliott Forensic Consulting, England

Professor Katia Gysling, Professor at the Faculty of Biological Sciences, Center for Addiction Studies, Pontificia Universidad Catolica de Chile, Republic of Chile

Professor Raka Jain, Professor of Chemistry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India

Dr Pamela Kaduri, Assistant Professor, Department of Psychiatry, University of Toronto and adjunct faculty, Muhimbili University of Health and Allied Sciences, United Republic of Tanzania (Rapporteur)

Dr Junichi Kitanaka, Associate Professor, Department of Pharmacology, Hyogo College of Medicine, Japan

Dr Afarin Rahimi-Movaghar, Professor of Psychiatry, Director of Iranian National Centre for Addiction Studies, Tehran University of Medical Sciences, Islamic Republic of Iran (Co-Chair)

Professor Sutisa Nudmamud-Thanoi, Associate Professor, Centre of Excellence in Medical Biotechnology, Naresuan University, Thailand

Professor Jason White, Adjunct Professor, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia (Chair)

Temporary advisers

Dr Simon Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, England

Dr Agnes Vitry, School of Pharmacy and Medical Sciences, University of South Australia, Australia

Professor Mayyada al Wazaify, School of Pharmacy, University of Jordan, Jordan

Professor Kim Wolff, Department of Analytical, Forensic and Addiction Science, King's College London, England

Representatives of other organizations

Professor Jallal Toufiq, Member, International Narcotics Control Board, Vienna, Austria

Ms Beate Hammond, Drug Control and Crime Prevention Officer, International Narcotics Control Board, Vienna, Austria

Mr Justice Tetley, Chief, Laboratory and Scientific Section, United Nations Office on Drugs and Crime, Vienna, Austria

Expert Committee on Drug Dependence (ECDD) Secretariat (WHO Headquarters, Geneva, Switzerland)

Ms Alma Alic, Ethics Officer, Office of Compliance, Risk Management and Ethics

Dr Gilles Forte, Secretary of the ECDD; Coordinator, Access to Medicines, Vaccines and Pharmaceuticals Cluster

Ms Dilkushi Poovendran, Technical Officer, ECDD Secretariat; Access to Medicines, Vaccines and Pharmaceuticals Cluster

Dr Vladimir Poznyak, Coordinator, Department of Mental Health and Substance Abuse

Mr Jakob Quirin, Associate Legal Officer, Office of the Legal Counsel

Dr Mariângela Simão, Assistant Director-General, Access to Medicines, Vaccines and Pharmaceuticals Cluster

Ms Wil de Zwart, Technical Officer, ECDD Secretariat; Access to Medicines, Vaccines and Pharmaceuticals Cluster

Abbreviations

AIDS	acquired immunodeficiency syndrome
CND	Commission on Narcotic Drugs
DALY	disability-adjusted life years
ECDD	Expert Committee on Drug Dependence
EMP	Essential Medicines and Health Products
INCB	International Narcotics Control Board
INN	International Nonproprietary Name
NPS	new psychoactive substances
THC	tetrahydrocannabinol
UNODC	United Nations Office on Drugs and Crime
US	United States
WHO	World Health Organization
INN	International Nonproprietary Name
NIDA	National Institute of Drug Abuse
NPS	new psychoactive substances
RCT	randomized controlled trial

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24689

